Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 355-360

  Ballentine Carter, H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

benign PSA; human kallikrein 2; precursor form of PSA; prostate specific antigen; PSA kinetics; unbound or free PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BENIGN TUMOR; CANCER THERAPY; MALIGNANT NEOPLASTIC DISEASE; PROSTATE CANCER; QUALITY OF LIFE; REVIEW;

DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; SENTINEL SURVEILLANCE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UNNECESSARY PROCEDURES;

EID: 84860856485     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.141     Document Type: Review

References (84)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
2. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS et al. Prevalence of prostate cancer among men with a prostate-specific antigen level , or 54.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
3. Lowrance WT, Scardino PT. Predictive models for newly diagnosed prostate cancer patients. Rev Urol 2009; 11: 117-126.
4. Tosoian J, Loeb S. PSA and beyond: The past, present, and future of investigative biomarkers for prostate cancer. Sci World J 2010; 10: 1919-1931.
5. Barbash GI, Glied SA. New technology and health care costs-The case of robot-Assisted surgery. N Engl J Med 2010; 363: 701-704.
6. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 2003; 170: S21-5; discussion S6-7.
7. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-732.
8. Bul M, Schroder FH. Screening for prostate cancer-The controversy continues, but can it be resolved? Acta Oncol 2011; 50 Suppl 1: 4-11.
9. Haas GP, Delongchamps NB, Jones RF, Chandan V, SerioAMet al. Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 2007; 99: 1484-1489.
10. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-1717.
11. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302: 1202-1209.
12. Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006; 94: 1361-1368. (Pubitemid 43772267)
13. Albertsen PC, Moore DF, Shih W, Lin Y, Li H et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011; 29: 1335-1341.
14. Hamilton AS, Albertsen PC, Johnson TK, Hoffman R, Morrell D et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 2011; 107: 576-584.
15. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-1123.
16. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: Risk assessment and treatment. J Urol 2007; 178: S14-9. (Pubitemid 47224952)
17. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006; 98: 1134-1141. (Pubitemid 44288788)
18. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, ChiaDet al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
19. McVey GP, McPhail S, Fowler S, McIntosh G, GillattDet al. Initial management of lowrisk localized prostate cancer in the UK: Analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int 2010; 106: 1161-1164.
20. Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F et al. Predictive and prognostic models in radical prostatectomy candidates: A critical analysis of the literature. Eur Urol 2010; 58: 687-700.
21. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
22. Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 2010; 8: 145.
23. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869-875.
24. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-2101. (Pubitemid 40617061)
25. van Den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG et al. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 2010; 116: 1281-1290.
26. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 1248-1253. (Pubitemid 41535365)
27. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI et al. Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-2190.
28. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 2011; 29: 2795-2800.
29. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-Term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-631.
30. Ulmert D, O'Brien MF, Bjartell AS, Lilja H. Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol 2009; 6: 384-391.
31. Steuber T, O'Brien MF, Lilja H. Serum markers for prostate cancer: A rational approach to the literature. Eur Urol 2008; 54: 31-40.
32. Lilja H. Biology of prostate-specific antigen. Urology 2003; 62: 27-33. (Pubitemid 37371887)
33. Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004; 63: 905-10; discussion 10-11.
34. Mikolajczyk SD, Rittenhouse HG. Tumor-Associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease. Rinsho Byori 2004; 52: 223-230.
35. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE et al. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747-752. (Pubitemid 20112095)
36. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-916. (Pubitemid 17147932)
37. Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schroder FH. The changing pattern of prostate cancer at the time of diagnosis: Characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999; 161: 1192-1198. (Pubitemid 29426116)
38. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938-1942.
39. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166: 2185-2188. (Pubitemid 33065253)
40. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002; 20: 4567-4573. (Pubitemid 35402960)
41. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-1451. (Pubitemid 27208886)
42. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997; 79: 528-537. (Pubitemid 27051778)
43. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-771. (Pubitemid 28259189)
44. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517-523. (Pubitemid 36132976)
45. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374. (Pubitemid 24037911)
46. KattanMW, Eastham JA, Wheeler TM, Maru N, Scardino PT et al. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-1797. (Pubitemid 37254930)
47. Bangma CH, Roobol MJ, Steyerberg EW. Predictive models in diagnosing indolent cancer. Cancer 2009; 115: 3100-3106.
48. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997; 57: 3111-3114. (Pubitemid 27351720)
49. Tremblay RR, Deperthes D, Tetu B, Dube JY. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol 1997; 150: 455-459. (Pubitemid 27073775)
50. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker. Urology 1997; 49: 857-862. (Pubitemid 27246953)
51. Kohli M, Rothberg PG, Feng C, Messing E, Joseph J et al. Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark 2010; 7: 101-108.
52. Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Huber A et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organconfined prostate cancer compared with prostate-specific antigen. Urology 2000; 55: 481-485. (Pubitemid 30157948)
53. Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screendetected men within the PSA range 4-10 ng/ml. Eur Urol 2007; 52: 1358-1364. (Pubitemid 47445980)
54. Haese A, Graefen M, Becker C, Noldus J, Katz J et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 2003; 54: 181-186. (Pubitemid 36120315)
55. Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A et al. Association of freeprostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 2005; 63: 13-18. (Pubitemid 40365386)
56. Wenske S, Korets R, Cronin AM, Vickers AJ, Fleisher M et al. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. Int J Cancer 2009; 124: 659-663.
57. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-Analysis. Eur Urol 2005; 48: 386-99; discussion 98-99.
58. Carter HB, Partin AW, Luderer AA, Metter EJ, Landis P et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 1997; 49: 379-384. (Pubitemid 27138680)
59. Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010; 183: 1779-1785.
60. Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004; 50: 1017-1025. (Pubitemid 38725789)
61. Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D et al. [22]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010; 183: 1355-1359.
62. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ et al. Serum proprostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004; 171: 2239-2244. (Pubitemid 38625443)
63. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [22]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010; 19: 1193-1200.
64. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG et al. A multicenter study of [22]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185: 1650-1655.
65. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H et al. Prostatespecific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: 921-927.
66. Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C et al. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009; 15: 7316-7321.
67. Isharwal S, Makarov DV, Sokoll LJ, Landis P, Marlow C et al. ProPSA and diagnostic biopsy tissueDNAcontent combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 2011; 77: 763.e1-6.
68. Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int 2009; 103: 578-587.
69. Ng MK, Van As N, Thomas K, Woode-Amissah R, Horwich A et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int 2009; 103: 872-876.
70. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-2220.
71. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW et al. Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity. Urology 1995; 45: 591-596.
72. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-135.
73. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-447. (Pubitemid 41124176)
74. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, ZinckeH et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174: 2191-2196. (Pubitemid 41611772)
75. Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF et al. Long-Term effects of finasteride on prostate specific antigen levels: Results from the prostate cancer prevention trial. J Urol 2005; 174: 877-881. (Pubitemid 41140621)
76. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ et al. Detection of lifethreatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98: 1521-1527. (Pubitemid 44680903)
77. van Den Bergh RC, Roemeling S, Roobol MJ, Wolters T, Schroder FH et al. Prostatespecific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer-A review. Eur Urol 2008; 54: 505-516.
78. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810-2816.
79. Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ et al. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: Data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008; 54: 1073-1080.
80. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostatespecific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398-403.
81. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011; 103: 462-469.
82. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439. (Pubitemid 41124175)
83. Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME et al. Canary Prostate Active Surveillance Study: Design of a multi-institutional active surveillance cohort and biorepository. Urology 2010; 75: 407-413.
84. http://www.policesupport.com/ (accessed 28 October 2011).